Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its ...

Celcuity (CELC) is back in focus after reporting pivotal Phase 3 VIKTORIA-1 data for gedatolisib in HR-positive, HER2-negative advanced breast cancer, expanding the VIKTORIA-2 program and preparing ...

(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...

Q1 2026 call: gedatolisib FDA PDUFA July 17, ASCO VIKTORIA-1 data, VIKTORIA-2 expansion & cash runway—read now.

Celcuity shares rose after the Phase 3 trial of a treatment for breast cancer was expanded to include endocrine-sensitive patients. Shares company rose 9.7% to $136.59 in late morning trading on ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC) and Rubicon Organics (ROMJF) with bullish sentiments. According to TipRanks.com, McCammon ...

Celcuity plans to submit the data to the FDA as a supplemental new drug application. If everything goes to plan, the FDA will ...

A replay of the webcast will be available on the Celcuity website following the live event. Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the ...

The primary efficacy analysis showed the gedatolisib triplet led to statistically significant and clinically meaningful PFS improvement.

On Thursday, Celcuity Inc. CELC announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a ...

If you are trying to figure out whether Celcuity stock still offers value after a strong run, the starting point is understanding what the current price is really pricing in. Celcuity recently closed ...

Celcuity shares rose in premarket trading Monday after the company reported encouraging results from its Phase 3 trial for ...